Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369435 | 1.00 | POLB (0.42) | POLBRAB9ADCUN1D1TP53SMN1; SMN2 | |
| SCHEMBL28996931 | 0.90 | TRPV1 (0.41) | EGFRTRPV1 | |
| SCHEMBL29366854 | 0.90 | TRPV1 (0.41) | EGFRTRPV1 | |
| SCHEMBL26332480 | 0.82 | DCUN1D1 (0.41) | POLBRAB9ADCUN1D1TP53SMN1; SMN2 | |
| SCHEMBL29366839 | 0.82 | DCUN1D1 (0.41) | POLBRAB9ADCUN1D1TP53SMN1; SMN2 | |
| SCHEMBL30356990 | 0.80 | EGFR (0.49) | POLBRAB9ADCUN1D1SMN1; SMN2EGFR | |
| SCHEMBL30357001 | 0.80 | EGFR (0.49) | POLBRAB9ADCUN1D1SMN1; SMN2EGFR | |
| SCHEMBL28996911 | 0.80 | EGFR (0.49) | POLBRAB9ADCUN1D1SMN1; SMN2EGFR | |
| SCHEMBL28996943 | 0.80 | EGFR (0.49) | POLBRAB9ADCUN1D1SMN1; SMN2EGFR | |
| SCHEMBL29369433 | 0.80 | EGFR (0.49) | POLBRAB9ADCUN1D1SMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | claimed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | SANOFI (FR) | 2023-08-24 | — | — | US | disclosed |
| CN-116057042-A | Acrylamide-substituted indane compounds and their therapeutic uses | 赛诺菲 | 2023-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265047-A1 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | IDH2, INA, IDH3A | POLB 2290/4885RAB9A 4379/4885DCUN1D1 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.